Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1 Introduction Imatinib (IMB, also known by its trade name of Gleevec/Glivec), is a type of chemotherapy medication approved by the Food and Drug Administration (FDA) in 2001 (Diculescu et al., 2009). As a pioneer tyrosine kinase inhibitor (TKI), it is applied to treat certain types of cancers such as chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), for patients in which the Philadelphia chromosome is positive (Ph+) (Qu et al., 2019).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
